GlobeNewswire Inc.··NaMoleculin Advances MIRACLE Study as Annamycin Shows Promise in AML Treatment
Moleculin Biotech releases CEO update on Phase 3 MIRACLE trial evaluating Annamycin for relapsed/refractory acute myeloid leukemia, with enrollment progressing on schedule.
MBRXclinical developmentPhase 3 trial